Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma

Blood

Volumn 117, Issue 2, 2011, Pages 585-590

  Chen, Yingtai ^a,b   Zheng, Tongzhang ^b   Lan, Qing ^c   Foss, Francine ^d   Kim, Christopher ^b   Chen, Xuezhong ^e   Dai, Min ^f   Li, Yumin ^a   Holford, Theodore ^b   Leaderer, Brian ^b   Boyle, Peter ^g   Chanock, Stephen J ^c   Rothman, Nathaniel ^c   Zhang, Yawei ^b  

^a LANZHOU UNIVERSITY   (China)

^b YALE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e GANSU PROVINCIAL HOSPITAL   (China)

^f PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^g International Prevention Research Institute   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON RECEPTOR; GAMMA INTERFERON RECEPTOR 2; INTERLEUKIN 5; INTERLEUKIN 7 RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BODY MASS; CANCER RISK; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; GENE INTERACTION; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; T CELL LYMPHOMA; TH1 CELL; TH2 CELL; UNITED STATES;

EID: 78751565019     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-295097     Document Type: Article

References (49)

1. Stallone D. The influence of obesity and its treatment on the immune system. Nutr Rev. 1994;52(2):37-50. (Pubitemid 24090160)
2. Cerhan JR, Bernstein L, Severson RK, et al. Anthropometrics, physical activity, related medical conditions, and the risk of non-Hodgkin lymphoma. Cancer Causes Control. 2005;16(10):1203-1214. (Pubitemid 46187570)
3. Chang ET, Hjalgrim H, Smedby KE, et al. Body mass index and risk of malignant lymphoma in Scandinavian men and women. J Natl Cancer Inst. 2005;97(3):210-218. (Pubitemid 40277371)
4. Fernberg P, Odenbro A, Bellocco R, Boffetta P, Pawitan Y, Adami J. Tobacco use, body mass index and the risk of malignant lymphomas: a nationwide cohort study in Sweden. Int J Cancer.2006;118(9):2298-2302.
5. Holly EA, Lele C, Bracci PM, McGrath MS. Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol. 1999;150(4):375-389.
6. MacInnis RJ, English DR, Hopper JL, Giles GG. Body size and composition and the risk of lymphohematopoietic malignancies. J Natl Cancer Inst. 2005;97(15):1154-1157. (Pubitemid 41511215)
7. Moller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer. 1994;30A(3):344-350. (Pubitemid 24152476)
8. Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol. 2005;23(21):4742-4754.
9. Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y. Association of obesity and cancer risk in Canada. Am J Epidemiol. 2004;159(3):259-268. (Pubitemid 38141655)
10. Pan SY, Mao Y, Ugnat AM. Physical activity, obesity, energy intake, and the risk of non-Hodgkin's lymphoma: a population-based case-control study. Am J Epidemiol. 2005;162(12):1162-1173. (Pubitemid 41785910)
11. Rapp K, Schroeder J, Klenk J, et al. Obesity and incidence of cancer: a large cohort study of over 145 000 adults in Austria. Br J Cancer. 2005;93(9):1062-1067.
12. Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni JF Jr. Relation of body mass index to cancer risk in 362 552 Swedish men. Cancer Causes Control. 2006;17(7):901-909.
13. Skibola CF, Holly EA, Forrest MS, et al. Body mass index, leptin and leptin receptor polymorphisms, and non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2004;13(5):779-786.
14. Willett EV, Skibola CF, Adamson P, et al. Non-Hodgkin's lymphoma, obesity and energy homeostasis polymorphisms. Br J Cancer. 2005;93(7):811-816. (Pubitemid 41486443)
15. Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control. 2001;12(1):13-21. (Pubitemid 32125897)
16. Bahl S, Cotterchio M, Kreiger N, Klar N. Antidepressant medication use and non-Hodgkin's lymphoma risk: no association. Am J Epidemiol. 2004;160(6):566-575. (Pubitemid 39215633)
17. Chiu BC, Gapstur SM, Greenland P, Wang R, Dyer A. Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(12):2348-2354. (Pubitemid 46048289)
18. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625-1638. (Pubitemid 36459468)
19. Willett EV, Morton LM, Hartge P, et al. Non-Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph Consortium. Int J Cancer. 2008;122(9):2062-2070.
20. Spilianakis CG, Lalioti MD, Town T, Lee GR, Flavell RA. Interchromosomal associations between alternatively expressed loci. Nature. 2005;435(7042):637- 645.
21. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev. 1996;9(4):532-562.
22. Foster CB, Chanock SJ. Mining variations in genes of innate and phagocytic immunity: current status and future prospects. Curr Opin Hematol. 2000;7(1):9-15.
23. Gergely L, Aleksza M, Varoczy L, et al. Intracellular IL-4/IFN-gamma producing peripheral T lymphocyte subsets in B cell non-Hodgkin's lymphoma patients. Eur J Haematol. 2004;72(5):336-341. (Pubitemid 38520731)
24. Keen LJ. The extent and analysis of cytokine and cytokine receptor gene polymorphism. Transpl Immunol. 2002;10(2-3):143-146.
25. Hofmann SR, Ettinger R, Zhou YJ, et al. Cytokines and their role in lymphoid development, differentiation and homeostasis. Curr Opin Allergy Clin Immunol. 2002;2(6):495-506. (Pubitemid 36105812)
26. Chiu BC, Weisenburger DD. An update of the epidemiology of non-Hodgkin's lymphoma. Clin Lymphoma. 2003;4(3):161-168.
27. Mori T, Takada R, Watanabe R, Okamoto S, Ikeda Y. T-helper (Th)1/Th2 imbalance in patients with previously untreated B-cell diffuse large cell lymphoma. Cancer Immunol Immunother. 2001;50(10):566-568. (Pubitemid 34028290)
28. Lan Q, Zheng T, Rothman N, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood. 2006;107(10):4101- 4108.
29. Zhang Y, Holford TR, Leaderer B, et al. Haircoloring product use and risk of non-Hodgkin's lymphoma: a population-based case-control study in Connecticut. Am J Epidemiol. 2004;159(2):148-154. (Pubitemid 38082523)
30. Zheng T, Holford TR, Leaderer B, et al. Diet and nutrient intakes and risk of non-Hodgkin's lymphoma in Connecticut women. Am J Epidemiol. 2004;159(5):454-466. (Pubitemid 38280291)
31. Jaffe ES, Stein H, Vardiman JW. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press;2001.
32. Sell H, Eckel J. Adipose tissue inflammation: novel insight into the role of macrophages and lymphocytes. Curr Opin Clin Nutr Metab Care. 2010;13(4):366-370.
33. Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uze G. The type I interferon receptor: structure, function, and evolution of a family business. J Interferon Cytokine Res. 1999;19(10):1069-1098. (Pubitemid 29502774)
34. Rocha VZ, Folco EJ, Sukhova G, et al. Interferongamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res. 2008;103(5):467-476.
35. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133-146. (Pubitemid 37328691)
36. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4 T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260(5107):547-549. (Pubitemid 23161621)
37. Waldele K, Schneider G, Ruckes T, Grassmann R. Interleukin-13 overexpression by tax transactivation: a potential autocrine stimulus in human T-cell leukemia virus-infected lymphocytes. J Virol. 2004;78(12):6081-6090. (Pubitemid 38715906)
38. Wang SS, Carreon JD, Hanchard B, Chanock S, Hisada M. Common genetic variants and risk for non-Hodgkin lymphoma and adult T-cell lymphoma/leukemia in Jamaica. Int J Cancer. 2009;125(6):1479-1482.
39. Sudo T, Nishikawa S, Ohno N, et al. Expression and function of the interleukin 7 receptor in murine lymphocytes. Proc Natl Acad Sci U S A. 1993;90(19):9125-9129.
40. Rolink A, Haasner D, Nishikawa S, Melchers F. Changes in frequencies of clonable pre B cells during life in different lymphoid organs of mice. Blood. 1993;81(9):2290-2300.
41. Van De Wiele CJ, Marino JH, Murray BW, Vo SS, Whetsell ME, Teague TK. Thymocytes between the beta-selection and positive selection checkpoints are nonresponsive to IL-7 as assessed by STAT-5 phosphorylation. J Immunol. 2004;172(7):4235-4244.
42. Giliani S, Mori L, de Saint Basile G, et al. Interleukin-7 receptor alpha (IL-7Ralpha) deficiency: cellular and molecular bases: analysis of clinical, immunological, and molecular features in 16 novel patients. Immunol Rev. 2005;203(1):110-126.
43. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol. 2006;7(1):27-38.
44. Wang SS, Cozen W, Cerhan JR, et al. Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res. 2007;67(10):5042-5054.
45. Bel Hadj Jrad B, Chatti A, Laatiri A, et al. Tumor necrosis factor promoter gene polymorphism associated with increased susceptibility to non-Hodgkin's lymphomas. Eur J Haematol. 2007;78(2):117-122.
46. Purdue MP, Lan Q, Kricker A, et al. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis. 2007;28(3):704-712.
47. Wang SS, Cerhan JR, Hartge P, et al. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res. 2006;66(19):9771-9780.
48. Spink CF, Keen LJ, Mensah FK, Law GR, Bidwell JL, Morgan GJ. Association between non-Hodgkin lymphoma and haplotypes in the TNF region. Br J Haematol. 2006;133(3):293-300.
49. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 2005;5(10):749-759.